Biomarin Pharmaceutical reported $519.36M in Sales Revenues for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Sales Change
Acadia Pharmaceuticals ACAD:US $ 115.47M 15.29M
Acorda Therapeutics ACOR:US $ 22.53M 14.43M
Alnylam Pharmaceuticals ALNY:US $ 213.26M 45.28M
Amgen AMGN:US $ 6238M 608M
Bayer BAYN:GR € 14639M 3521M
Biogen BIIB:US $ 2531.8M 202M
Biomarin Pharmaceutical BMRN:US $ 519.36M 69.55M
Bluebird Bio BLUE:US $ 1.94M 0.34M
Gilead Sciences GILD:US $ 6590M 654M
Insmed INSM:US $ 53.11M 3.02M
Intercept Pharmaceuticals ICPT:US $ 88.58M 3.82M
Moderna Inc MRNA:US 6.07B 1.14B
Ptc Therapeutics PTCT:US $ 148.74M 16.49M
Puma Biotechnology PBYI:US $ 45.74M 9.62M
Regeneron Pharmaceuticals REGN:US $ 2965.1M 1986.6M
Roche Holding ROG:VX 16.44B 474M
Sangamo Biosciences SGMO:US $ 28.23M 0.24M
Sarepta Therapeutics SRPT:US $ 210.83M 9.37M
Seattle Genetics SGEN:US $ 426.46M 3.39M
Ultragenyx Pharmaceutical RARE:US $ 79.94M 3.45M
United Therapeutics UTHR:US $ 461.9M 46.7M
Vertex Pharmaceuticals VRTX:US $ 2097.5M 24.94M
YTE INCY:US $ 733.24M 129.62M